scholarly journals Anal squamous carcinoma: a new AIDS-defining cancer? Case report and literature review

2012 ◽  
Vol 54 (6) ◽  
pp. 345-348 ◽  
Author(s):  
Marcelo Corti ◽  
María F. Villafañe ◽  
Esteban Marona ◽  
Daniel Lewi

Squamous anal cell carcinoma is a rare malignancy that represents the 1.5% to 2% of all the lower digestive tract cancers. However, an increased incidence of invasive anal carcinoma is observed in HIV-seropositive population since the widespread of highly active antiretroviral therapy. Human papillomavirus is strongly associated with the pathogenesis of anal cancer. Anal intercourse and a high number of sexual partners appear to be risk factors to develop anal cancer in both sexes. Anal pain, bleeding and a palpable lesion in the anal canal are the most common clinical features. Endo-anal ultrasound is the best diagnosis method to evaluate the tumor size, the tumor extension and the infiltration of the sphincter muscle complex. Chemoradiotherapy plus antiretroviral therapy are the recommended treatments for all stages of localized squamous cell carcinoma of the anal canal in HIV-seropositive patients because of its high rate of cure. Here we present an HIV patient who developed a carcinoma of the anal canal after a long time of HIV infection under highly active antiretroviral therapy with a good virological and immunological response.

AIDS ◽  
1998 ◽  
Vol 12 (12) ◽  
pp. 1459-1464 ◽  
Author(s):  
Isabelle Heard ◽  
Valérie Schmitz ◽  
Dominique Costagliola ◽  
Gérard Orth ◽  
Michel D. Kazatchkine

2004 ◽  
Vol 190 (6) ◽  
pp. 1046-1054 ◽  
Author(s):  
Cunlin Wang ◽  
David Vlahov ◽  
Noya Galai ◽  
Joseph Bareta ◽  
Steffanie A. Strathdee ◽  
...  

2002 ◽  
Vol 13 (4) ◽  
pp. 273-274 ◽  
Author(s):  
M Kawsar ◽  
S El-Gadi

We report a case of subcutaneous granulomatous lesions developed in a HIV seropositive man, related to ritonavir therapy. The importance of close monitoring and investigations of patients developing unusual side effects during highly active antiretroviral therapy (HAART) is demonstrated.


AIDS ◽  
1999 ◽  
Vol 13 (11) ◽  
pp. 1351-1357 ◽  
Author(s):  
Abby H. Shevitz ◽  
Tamsin A. Knox ◽  
Donna Spiegelman ◽  
Ronenn Roubenoff ◽  
Sherwood L. Gorbach ◽  
...  

2005 ◽  
Vol 32 (5) ◽  
pp. 314-320 ◽  
Author(s):  
Catherine Diamond ◽  
Thomas H. Taylor ◽  
Tabatha Aboumrad ◽  
Deborah Bringman ◽  
Hoda Anton-Culver

2006 ◽  
Vol 10 (3) ◽  
pp. 142-146
Author(s):  
Najwa Somani ◽  
Gregory Bondy ◽  
Richard I. Crawford

Background: Acne vulgaris may occur as part of immune reconstitution in human immunodeficiency virus (HIV)-seropositive patients on highly active antiretroviral therapy (HAART). Tetracyclines are a common acne treatment. Hypertriglyceridemia has not been reported as a side effect of this drug class. Objective: We report a case of an HIV-seropositive man on HAART (CD4 count 450 cells/μL) who developed isolated hypertriglyceridemia (> 13 mmol/L) after three separate challenges with minocycline or tetracycline, improving each time therapy was discontinued. Results: Based on a review of the literature, this is the first reported case of hypertriglyceridemia with minocycline or tetracycline therapy. No published reports have examined the safety of tetracyclines in the setting of HIV or HAART. Conclusion: A strong temporal association between tetracycline use and hypertriglyceridemia was found without an alternate explanation for the observed lipid profile. Given the common use of tetracyclines in dermatology, we feel that this is an important observation to report.


Sign in / Sign up

Export Citation Format

Share Document